Understanding the tests that we order: screening for anti-NMDA receptor encephalitis in first episode psychosis.
Saved in:
| Title: | Understanding the tests that we order: screening for anti-NMDA receptor encephalitis in first episode psychosis. |
|---|---|
| Authors: | Singer, Joel (AUTHOR), Sachdev, Perminder (AUTHOR), Mohan, Adith (AUTHOR) |
| Source: | Australasian Psychiatry. Apr2020, Vol. 28 Issue 2, p199-201. 3p. |
| Abstract: | |
| Copyright of Australasian Psychiatry is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | <bold>Objective: </bold>The current guidelines recommend screening all patients with first episode psychosis (FEP) for anti-NMDA receptor encephalitis. This paper explores the pitfalls of this strategy.<bold>Conclusion: </bold>Screening for anti-NMDA receptor encephalitis in patients with FEP when the pre-test probability based on the clinical presentation is low creates a risk of false positive results. Testing based on clinical suspicion would be preferable. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 10398562 |
| DOI: | 10.1177/1039856220905299 |
